The US Food and Drug Administration has approved an expanded label for Sanofi's (SNY) type 1 diabetes treatment Tzield, allowing its use in children aged 8 to 17 who have recently been diagnosed with stage 3 of the disease.

Spyre Therapeutics (SYRE) said its experimental ulcerative colitis treatment significantly reduced disease severity in a mid-stage clinical trial, marking a key milestone for the biotech's inflammation pipeline.

Shares in Elicio Therapeutics (ELTX) fell roughly 72% after the biotech company's experimental pancreatic cancer vaccine failed to meaningfully extend the time patients lived without disease recurrence, missing the primary endpoint of a mid-stage clinical study.

Treatments based on the messenger RNA technology behind Covid-19 vaccines are demonstrating lasting efficacy against melanoma and showing early promise in pancreatic and brain cancers long considered beyond the reach of immunotherapy, researchers reported at a major oncology conference this week.

Europe's illicit drug market is undergoing a significant transformation, with synthetic opioids posing an increasing threat even as the region continues to record far fewer fatal overdoses than North America, the European Union Drugs Agency warned in its annual report.

Sanofi (SNY) has halted a Phase 3 clinical trial of riliprubart, an experimental treatment for a rare neurological disorder, after an interim analysis concluded the drug was unlikely to demonstrate sufficient efficacy.

AstraZeneca (AZN) has been found to have breached UK pharmaceutical marketing rules for the latest in a series of cases involving the LinkedIn activity of its employees, with the country's self-regulatory watchdog identifying eight separate violations.

Artificial intelligence is generating meaningful time savings for healthcare professionals, but the majority of clinicians report that training in the technology remains inadequate, inconsistent or unavailable at their organizations, according to a global survey published Tuesday by Philips (PHIA).

Federal litigation linking Pfizer's (PFE) Depo-Provera birth control injection to brain tumors has swelled to more than 5,500 cases after roughly 1,700 new lawsuits were filed in a single month, with a critical court hearing this week set to determine whether the claims can proceed to trial.

The Food and Drug Administration is conducting a safety investigation into mifepristone, the most widely used abortion pill in the US, in a move that could provide the Trump administration with a regulatory mechanism to restrict access to the drug, according to the Wall Street Journal.

AlzeCure Pharma (ALZCUR) has signed a collaboration and out-licensing agreement with Eli Lilly (LLY) granting the US drugmaker global rights to an Alzheimer's drug candidate in a deal that could exceed $1bn in total value.

Takeda (TAK) swung to a net loss for its 2025 fiscal year after recording a $2.5bn legal charge stemming from a landmark antitrust verdict, the Japanese drugmaker said on June 5.

Cancer patients across India are struggling to obtain platinum-based chemotherapy drugs as a sharp rise in the price of the raw material squeezes manufacturers and depletes hospital stockpiles, forcing patients to scour pharmacies for supplies.

Gilead Sciences (GILD) has suffered another clinical defeat for its flagship antibody-drug conjugate Trodelvy, after a phase 3 trial in first-line lung cancer failed — intensifying the race among Merck, AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) to capture the indication.

State Bank of India (SBIN) is preparing to join a consortium of global lenders financing Sun Pharmaceutical Industries' (SUNPHARMA) $12bn acquisition of Organon & Co (OGN), committing up to $1bn pending board approval, according to people familiar with the matter.

Zealand Pharma (ZEAL) shares slid 24% in European afternoon trading, bringing year-to-date losses to around 47%, after partner Boehringer Ingelheim released full results from a late-stage trial of survodutide — an experimental obesity injection — showing a high rate of patient dropouts due to gastrointestinal side effects.

GSK (GSK) has agreed to acquire U.S.-listed cancer drug developer Nuvalent (NUVL) for $10.6 billion in its largest deal in more than a decade, marking a decisive shift toward oncology under new chief executive Luke Miels as the British drugmaker races to build scale in lung cancer treatments.

Centene (CNC) has offered voluntary separation packages to employees across most of its workforce following steep declines in enrollment in its Affordable Care Act health plans, as the lapse of pandemic-era subsidies weighs on its commercial business.

Roche (RHHBY) said it will press ahead with a planned €600mn investment in a new diagnostic production facility in Penzberg, Germany, bucking a trend of pharmaceutical companies scaling back spending in the country in response to government healthcare cost-cutting measures.

The Alzheimer's disease drug pipeline has reached record size and diversity, with researchers increasingly moving beyond the amyloid-plaque approach that has dominated the field for decades in favor of treatments targeting inflammation, immune processes, neurotransmitters and tau protein.